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Forkhead box p3 (Foxp3)-expressing regulatory T cells are key mediators of peripheral tolerance suppressing
undesirable immune responses. Ectopic expression of Foxp3 confers regulatory T cell phenotype to conventional T
cells, lending itself to therapeutic use in the prevention of autoimmunity and transplant rejection. Here, we show that
adoptive transfer of polyclonal, wild-type T cells transduced with an inducible form of Foxp3 (iFoxp3) can be used to
suppress immune responses on demand. In contrast to Foxp3-transduced cells, iFoxp3-transduced cells home
‘‘correctly’’ into secondary lymphoid organs, where they expand and participate in immune responses. Upon induction
of iFoxp3, the cells assume regulatory T cell phenotype and start to suppress the response they initially partook in
without causing systemic immunosuppression. We used this approach to suppress collagen-induced arthritis, in which
conventional Foxp3-transduced cells failed to show any effect. This provides us with a generally applicable strategy to
specifically halt immune responses on demand without prior knowledge of the antigens involved.
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Introduction
Transplant rejection and autoimmune diseases ranging
from rheumatoid arthritis, type I diabetes, and multiple
sclerosis to inﬂammatory bowel disease—as diverse as they
might appear—all have the same underlying problem: the
launch of an undesirable immune response [1]. Equally
similar are the current approaches to treat these conditions,
which are generally based on drugs that lead to systemic
immunosuppression [2]. Thus, the induction of speciﬁc
t o l e r a n c ei ss e e na st h e‘‘Holy Grail’’ of therapeutic
approaches [3].
The discovery that the immune system evolved regulatory T
(TR) cells to stop undesirable immune responses, such as
autoimmunity [4] and the rejection of the fetus [5–7], is of
obvious therapeutic promise [8]. Indeed, TR cells have already
been shown to be capable of fulﬁlling such functions [9].
However, the translation of experimental ﬁndings into actual
therapeutic approaches is hampered by a variety of problems.
Under experimental conditions, antigen-speciﬁc tolerance
can be achieved by using TR cells from TCR-transgenic
animals or by ex vivo expansion of antigen-speciﬁc TR cells
[9–11]. However, it is difﬁcult to imagine how a TCR
transgenic approach can be translated into a generally
applicable therapy. The antigen-speciﬁc ex vivo expansion
of TR cells [9–11], or in vivo conversion of helper T cells (TH)
into TR cells [12], is more feasible, albeit still problematic.
They not only rely on the knowledge of, or at least access to
the antigens involved in the pathological immune response,
but are also time consuming and complicated when applied
in a therapeutic context [8,13].
There are also conceptual problems. The lack or malfunc-
tion of TR cells is suspected to be at the root of many
autoimmune diseases [14,15]. In these cases, it might be
impossible to obtain and expand functional, antigen-speciﬁc
TR cells, as they may not exist in the host in the ﬁrst place. In
principle, this problem can be circumvented by the con-
version of conventional T cells into TR cells, either by TGF-ß–
mediated induction [16–18] or ectopic expression of the
lineage factor Forkhead box p3 (Foxp3) (NP_473380) [19–
21]. However, without enriching antigen-speciﬁc ‘‘induced TR
cells,’’ this is likely to be of limited beneﬁt and may lead to
systemic immune-suppression [11,22–24]. A further problem
with TGF-ß–induced TR cells is that their phenotype seems to
be unstable [25,26], although the presence of retinoic acid
appears to stabilize the conversion [27,28].
Here, we present a strategy to suppress undesirable
immune responses in an antigen-speciﬁc fashion without
prior knowledge of the antigens involved. We accomplish this
by adoptive transfer of a small number of polyclonal TH cells
transduced with a genetically engineered, inducible form of
Foxp3 (iFoxp3). CD4
þCD25
  cells transduced with iFoxp3
(TH::iFoxp3) initially retain their ‘‘proinﬂammatory’’ pheno-
type. They home ‘‘correctly’’ into the secondary lymphoid
organs and partake in immune responses. Once the TH::i-
Foxp3 cells have expanded in an antigen-speciﬁc fashion,
they can be converted to TR cell phenotype on demand by
inducing iFoxp3, thereby stopping the immune response they
partook in.
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Failure of Polyclonal TH::Foxp3 Cells to Suppress Collagen-
Induced Arthritis
Encouraged by the initial ﬁnding that polyclonal
CD4
þCD25
  T cells transduced with Foxp3 (TH::Foxp3) can
prevent and treat colitis in lymphopenic animals [19,29], we,
like others [23,30,31], set out to test whether this can be used
as a general strategy to prevent and treat autoimmune
diseases. To test this hypothesis, we used collagen-induced
arthritis (CIA), which is a well-established murine model of
human rheumatoid arthritis [32]. To obtain TH::Foxp3 cells,
we transduced CD4
þCD25
  T cells with a murine leukemia
virus (MLV)-based retroviral vector carrying a Foxp3-IRES-
GFP cassette (m6pg[Foxp3]) (Figure S1). We immunized male
DBA/1 mice with chicken collagen type II (cII) in complete
Freund’s adjuvant (CFA). In this model, we observe the ﬁrst
clinical symptoms of arthritis on day 19 after immunization,
with the average clinical score reaching a plateau around day
35. Injection of 1 3 10
6 TH::Foxp3 cells 1 d prior to
immunization did not have any signiﬁcant impact on the
outcome of the arthritis. It neither delayed the time of disease
onset, nor did it alter disease progression (Figure 1A). The
failure of polyclonal TH::Foxp3 cells to show any beneﬁcial
effect on the outcome of CIA under these experimental
conditions is in agreement with the ﬁndings of others [31]
and led us to reassess the approach per se. Therefore, we
decided to examine the homing, expansion, and participation
of TH::Foxp3 cells in immune responses.
Altered Homing Behavior of TH::Foxp3 Cells
The decision whether to launch or suppress an immune
response is made within the secondary lymphoid organs [33].
This makes ‘‘correct’’ homing of the adoptively transferred
cells an essential requirement for cytotherapy, as otherwise
their participation in immune responses might be severely
limited.
We therefore compared the homing of TH::Foxp3 cells to
that of m6pg[control]-transduced CD4
þCD25
 T( T H::control)
cells (Figure S1) and freshly isolated CFSE-labeled
CD4
þCD25
  (TH) cells or CD4
þCD25
þ (TR) cells. A total of 1
3 10
6 cells were injected into wild-type Balb/c mice. After 48
h, we isolated the lymphocytes from the various tissues and
analyzed them by ﬂow cytometry. The transferred cells were
identiﬁed based on either their green ﬂuorescent protein
(GFP) coexpression or CFSE label. TH::control cells, like TR
and TH cells, could be detected at comparable frequencies in
blood, and inguinal and iliac lymph nodes, as well as the
spleen (Figure 1B and 1C). In contrast, the homing of
TH::Foxp3 cells into the lymph nodes appeared to be
defective and their homing into the spleen slightly impaired.
Instead, a large number of these cells could be found in the
liver (Figure 1C). The data suggest that ectopic expression of
Foxp3 substantially altered the homing behavior of the
transduced cells.
Foxp3-Mediated Regulation of CD62L
The absence of T cells from the peripheral lymph nodes is
one of the key features of CD62L-deﬁcient (sell
 / ) mice [34].
Figure 1. Polyclonal TH::Foxp3 Cells Fail to Suppress CIA and Exhibit
Altered Homing Behavior
(A) Arthritis was induced on day 0 by immunization with cII in CFA. Mice
that did not receive any further treatment (black, n ¼ 27) and mice that
received 1310
6 TH::Foxp3 cells 1 d prior to immunization (red, n¼7) are
shown. The average arthritis scores of all mice in the two groups are
shown.
(B and C) Comparison of the homing behavior of (B) CFSE-labeled TH
(black) and TR (red) cells and (C) GFP-expressing TH::control (black) and
TH::Foxp3 (red) cells. A total of 1 3 10
6 cells were transferred into each
mouse (TH, n ¼ 3; TR, n ¼ 3; control, n ¼ 4; and Foxp3, n ¼ 6), and the
tissues were analyzed 48 h later by flow cytometry. The diagrams
represent the percentage of cells in each tissue, calculated from the total
number of cells recovered in all tissues together (1.2 3 10
5 6 0.1 3 10
5
TH cells and 1.1 3 10
5 6 0.2 3 10
5 TR cells; 8.3 3 10
4 6 2.7 3 10
4
TH::control cells and 5.1 3 10
4 6 0.9 3 10
4 TH::Foxp3: cells; values 6
SEM). Error-bars represent the SEM.
doi:10.1371/journal.pbio.0060276.g001
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Author Summary
Autoimmune diseases come in many diverse forms—such as
rheumatoid arthritis, type I diabetes, multiple sclerosis, and
inflammatory bowel disease—yet all share the same underlying
cause, the launch of a detrimental immune response. In healthy
individuals, a specialized immune cell type called regulatory T cells
prevents these undesirable immune responses. Here, we present a
strategy to suppress undesirable immune responses using genet-
ically modified proinflammatory T cells that participate in these
inappropriate immune responses until they are activated with a
drug. At this point, the genetic modification causes them to change
their behavior to that of regulatory T cells. Using a mouse model, we
demonstrate that this approach can be used to stop undesirable
immune responses on demand with minimal intervention.CD62L (L-selectin) plays a key role in the homing of
lymphocytes into these tissues by allowing their attachment
to high endothelial venules [35]. Activation of T cells leads to
endoproteolytic shedding of CD62L from the surface of the
cells, involving the matrix-metalloprotease Adam17 [36].
Therefore, we investigated whether the altered homing
behavior of TH::Foxp3 cells is due to Foxp3-mediated effects
on the surface expression of CD62L.
We found that the majority of freshly isolated TH and TR
cells are CD62L
hi (Figure 2A and 2B). Activation of the cells
for 72 h with anti-CD3/anti-CD28/IL-2 led to a down-
regulation of CD62L surface expression, which was more
marked in TR than TH cells (Figures 2C and S2A). To assess
whether this is due to an increase in Adam17 activity in TR
cells, we activated freshly isolated splenocytes with PMA and
compared the surface expression of CD62L on Foxp3
þ (TR)
and Foxp3
  (TH) CD4
þ T cells. The rate of CD62L shedding
appeared to be very similar for both cell types and could be
completely blocked by the Adam17 inhibitor TAPI-2 (Figure
2D). This suggests that an additional Adam17-independent
mechanism in TR cells is responsible for the difference in
CD62L surface expression observed upon activation of TR
and TH cells.
To further investigate this, we examined CD62L expression
in TH::Foxp3 cells. We transduced CD4
þCD25
  cells with
either m6p8[Foxp3] or m6p8[control]. The cells carrying the
vector were identiﬁed based on their coexpression of
ratCD8a (Figure S1). Whereas TH::control cells exhibited
some down-regulation of surface CD62L upon activation with
anti-CD3/IL-2, this was substantially more marked in
Figure 2. Foxp3-Mediated Regulation of CD62L
(A–D) CD62L expression on CD4
þFoxp3
  TH cells (black) and CD4
þFoxp3
þ TR cells (red).
(A) Representative FACS profiles for CD62L expression on TH and TR cells prepared from spleen (n¼3 in each case) with unstained TH cells (grey) shown
as control.
(B) Mean fluorescence intensity (MFI) of CD62L on TH and TR cells from indicated tissues (n ¼ 2 in each case).
(C) Representative FACS profiles of CD4
þCD25
  TH (black) and CD4
þCD25
þ TR (red) cells activated for 72 h (n ¼ 3 in each case).
(D) Total splenocytes were incubated in the absence of any treatment (solid line) or activated by addition of 100 ng/ml PMA in the presence (dashed
line) or absence (dotted line) of 50 lM TAPI-2 (n ¼ 3 in each case).
(E–I) CD62L expression in TH::control (black) and TH::Foxp3 cells (red). CD4
þCD25
  cells were activated for 36 h and transduced (0 h) with either
m6p8[control] (black line; n¼3) or m6p8[Foxp3] (red line; n¼3). (E and F) Representative FACS profiles of CD62L expression on transduced cells at (E) 0
h and (F) 24 h after transduction.
(G) Percentage of CD62L
hi cells within the transduced populations in the presence (dashed line) or absence (solid line) of 50 lM TAPI-2.
(H) Amount of soluble CD62L in the supernatant measured by ELISA (representative of two independent experiments).
(I) Relative CD62L expression in CD4
þCD25
  TH and CD4
þCD25
þ TR cells (n ¼ 3 in each case), as well as TH::control and TH::Foxp3 cells 48 h after
transduction (n ¼ 2 in each case) determined by qPCR and normalized to HPRT. Error bars represent the SEM.
doi:10.1371/journal.pbio.0060276.g002
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Suppressing Immune Responses with iFoxp3TH::Foxp3 cells (Figure 2E and 2F). For the ﬁrst 24 h, TAPI-2
appeared to partially inhibit the loss of surface CD62L on
TH::Foxp3 cells, but it did not halt the steady decrease in
surface CD62L over an extended period of time (Figure 2G).
The CD62L down-regulation in TH::control cells was accom-
panied by an accumulation of soluble CD62L in the culture
supernatant. This was not the case for TH::Foxp3 cells (Figure
2H), suggesting that in these cells, CD62L surface expression
is regulated by a mechanism other than shedding. As Foxp3 is
known to be a transcriptional regulator [37–40], we inves-
tigated whether it affects CD62L transcription. The CD62L
mRNA expression level was reduced in both TH::Foxp3 and
TH::control cells compared to freshly isolated TH and TR cells
(Figure 2I). However, the level of CD62L transcript was 7.2-
fold lower in TH::Foxp3 cells than in TH::control cells. The
data suggest that upon activation of the cells, CD62L is
further down-regulated on a transcriptional level by Foxp3.
It is noteworthy that retroviral transduction requires at
least some degree of activation of the cell to allow for
transgene integration. In this context, the expression of
Foxp3 led to a very marked and sustained down-regulation of
surface CD62L expression. This is likely to be a major
contributor to the altered homing behavior of TH::Foxp3
cells. Although the down-regulation of CD62L upon activa-
tion is similarly more evident in thymically derived TR cells
than TH cells (Figure S2A and S2B), albeit less marked than in
TH::Foxp3 (Figure 2I), it does not appear to interfere with the
cells ability to home into peripheral lymph nodes (Figure
S2C).
iFoxp3—an Engineered Inducible Lineage Factor
The ‘‘incorrect’’ homing of polyclonal TH::Foxp3 cells
might well contribute to their lack of showing any beneﬁcial
effect in CIA [31] (Figure 1A) and other animal models of
autoimmune disease [11]. However, one might question
whether our initial approach had any merit in the ﬁrst place,
since the transfer of polyclonal TH::Foxp3 cells will only
marginally increase the number of suppressive cells that
recognize a particular antigen. Indeed, treatment with
polyclonal TH::Foxp3 cells more or less mimics polyclonal
TR cell therapy, which in contrast to approaches using
antigen-speciﬁc TR cells, appears to be of limited beneﬁt
[22–24,41].
We decided to develop an alternative strategy, allowing us
to convert the lineage commitment of conventional TH cells
to that of TR cells after their antigen-speciﬁc expansion in
vivo. To achieve this, we created an inducible Foxp3 (iFoxp3)
that is constitutively expressed, but only becomes functionally
active upon induction. Polyclonal, primary TH cells trans-
duced with iFoxp3 (TH::iFoxp3 cells) should act like conven-
tional T cells, retain their homing behavior, participate in
immune responses, and expand in an antigen-speciﬁc
fashion. This antigen-speciﬁc in vivo expansion of TH::iFoxp3
cells should allow us to speciﬁcally switch off immune
responses on demand by inducing iFoxp3.
We fused a modiﬁed estrogen receptor (ERT2) to the C-
terminal end of Foxp3 and cloned it into the m6p vector
(Figure 3A and 3B). ERT2 only responds to tamoxifen and its
metabolites such as 4-hydroxytamoxifen (4-OHT), but not
estrogen [42]. In the absence of induction, iFoxp3 is retained
in the cytoplasm and kept inactive by heat shock proteins
binding to the ERT2 part of the fusion protein [43]. To
conﬁrm the inducible nature of iFoxp3, we transduced
CD4
þCD25
  cells with m6p carrying a GFP-tagged iFoxp3
(m6p8[GFP-iFoxp3]). This allowed us to assess the induction
of iFoxp3 based on the translocation of the fusion protein
from the cytoplasm into the nucleus. We induced iFoxp3 in
vitro by exposure to 4-OHT for 48 h (Figure 3C) or in vivo
after adoptive transfer of the transduced cells into wild-type
Balb/c mice by intraperitoneal (i.p.) injections of tamoxifen
(Figure 3D). In either case, iFoxp3 translocated into the
nucleus in about 60%–70% of the transduced cells at the time
of microscopic analysis, conﬁrming its inducible nature.
Induction of Suppressor Function in TH::iFoxp3 Cells
A key requirement for our strategy is that iFoxp3 can be
used to induce TR cell phenotype on demand. We therefore
tested TH::iFoxp3 cells for hallmark features of TR cells such
as sustained up-regulation of CD25, in vitro anergy to anti-
CD3-stimulation, and suppression of target cells [4] before
and after induction of iFoxp3. Whereas TH::Foxp3 cells were
anergic (Figure 3E), suppressed the proliferation of cocul-
tured CD4
þCD25
  cells (Figure 3F), and exhibited up-
regulation of CD25 (Figure 3G), TH::iFoxp3 cells did so only
after induction of iFoxp3 with 4-OHT. This demonstrates
that, at least in vitro, TH::iFoxp3 cells appear to behave like
conventional TH cells and only assume the phenotype of TR
cells upon the induction of iFoxp3.
TH::iFoxp3 Home Like Naive CD4
þ T Cells
From our observations with TH::control cells, we already
knew that transduction per se did not appear to alter the
homing behavior of the cells (Figure 1B and 1C). Nevertheless,
we wanted to verify that noninduced iFoxp3 neither changes
the expression of CD62L nor signiﬁcantly alters the homing
behavior of the TH::iFoxp3 cells. We found that in the absence
of iFoxp3 induction, CD62L expression remained unchanged
in TH::iFoxp3 compared to TH::control cells (Figure 3H and
3I). This is in stark contrast to our observations made for
TH::Foxp3 cells (Figure 2E to 2I). To assess the homing
behavior of the cells, we used the same approach as described
above. We found that the homing behavior of TH::iFoxp3 cells
was comparable to that of TH::control cells (Figure 3J) and
thus very similar to that of naive TH and TR cells (Figure 1B).
Antigen-Specific In Vivo Expansion of TH::iFoxp3 Cells
To assess whether TH::Foxp3 and TH::iFoxp3 cells expand
upon antigenic challenge in vivo, we transferred transduced
cells prepared from DO11.10xSCID/Balb/c mice that ex-
pressed an ovalbumin (ova)-speciﬁc TCR, into wild-type
Balb/c mice. We transferred 5 3 10
4 cells containing a
mixture of 2 3 10
4 TH::iFoxp3 cells and 3 3 10
4 non-
transduced cells (transduction efﬁciency of 40%) with the
transduced population being clearly identiﬁable based on the
coexpression of GFP. TH::iFoxp3 cells expanded upon
immunization with ova in CFA by a factor of 12 in the
draining lymph nodes and by a factor of 37.5 in the spleen
(Figure 4A). In contrast, TH::Foxp3 cells only exhibited a very
modest expansion, by a factor of 3.6 in the lymph nodes and
4.4 in the spleen. This could have been due to the TH::Foxp3
cells suppressing the ova-speciﬁc immune response and
thereby impeding their own expansion. However, the levels
of ova-speciﬁc antibodies in the serum were the same,
independent of whether the mice had received TH::Foxp3
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(A) Diagram of iFoxp3 containing retroviral vectors m6pg[iFoxp3] either coexpressing GFP or a GPI-linked ratCD8 a-chain m6p8[iFoxp3], and m6p8[GFP-
iFoxp3], which contains a fusion of GFP and iFoxp3.
(B) MFI of intracellular stain for Foxp3 in TH::Foxp3 and TH::iFoxp3 cells compared to CD4
þ TR and TH cells (n ¼ 2 in each case).
(C and D) Subcellular localization of GFP-iFoxp3 in TH::GFP-iFoxp3 cells (C) in vitro after 48 h in the presence or absence of 50 nM 4-OHT or (D) in vivo
after three injections of tamoxifen or carrier.
(E–G) Gain of TR cell function upon induction of iFoxp3.
(E) Proliferation of TH::control, TH::Foxp3, and TH::iFoxp3 cells upon anti-CD3e (0.6 lg/ml) stimulation measured by
3H-thymidine incorporation in the
absence (white bars; n ¼ 3 in each case) or presence of 50 nM 4-OHT (grey bars; n ¼ 3 in each case).
(F) A total of 1310
5 CFSE-labeled CD4
þCD25
  target T cells were cocultured with 1 310
5 TH::control, TH::Foxp3 or TH::iFoxp3 cells and activated with
anti-CD3e (0.6lg/ml) (n¼2 in each case). The proliferation of target cells was measured based on CFSE dilution after 72 h, and the percentage of cells
that had undergone at least one cell cycle is shown. The assay was performed in the absence (white bars) or the presence (grey bars) of 50 nM 4-OHT
added to the transduced cells 24 h prior to setup.
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Suppressing Immune Responses with iFoxp3or TH::iFoxp3 cells, suggesting this was not the case (Figure
4B). Our data demonstrates a clear expansion of TH::iFoxp3
cells, which is consistent with their participation in the
immune response against ova. This in vivo expansion upon
antigen exposure is considerably less marked in TH::Foxp3
cells.
Next, we investigated whether the in vivo expanded ova-
speciﬁc TH::iFoxp3 cells can be induced to suppress the very
(G) MFI of CD25 48 h after transduction on TH::control, TH::Foxp3, and TH::iFoxp3 in the absence (white bars; n¼2 in each case) or presence of 50 nM 4-
OHT (grey bars; n ¼ 2 in each case).
(H and I) Comparison of CD62L expression on TH::control, TH::Foxp3, and TH::iFoxp3 48 h after transduction with m6p8.
(H) Representative FACS profiles of CD62L expression (n ¼ 2 in each case).
(I) Percentage of CD62L
hi cells within the transduced populations.
(J) Comparison of the homing behavior of TH::control (black) and TH::iFoxp3 (red) cells. A total of 1 3 10
6 cells were transferred into each mouse
(TH::control, n¼2; TH::iFoxp3, n¼3), and the tissues were analyzed 48 h later by flow cytometry. The diagrams represent the percentage of cells in each
tissue calculated from the total number of cells recovered in all tissues together (5.4 3 10
5 6 0.7 3 10
5 TH::control cells and 3.1 3 10
5 6 0.4 3 10
5
TH::iFoxp3 cells; values 6 SEM).
doi:10.1371/journal.pbio.0060276.g003
Figure 4. TH::iFoxp3 Cells Partake in the Immune Response and Suppress It upon Induction
(A–C) Balb/c mice received 2310
4 TH::Foxp3 or TH::iFoxp3 cells prepared from DO11.10xSCID mice before being immunized s.c. with either ova in CFA
(þova) or CFA alone ( ova) (n ¼ 3 in each case).
(A) The frequency of GFP
þcells was measured eight days after immunization and the relative expansion was calculated as %GFP
þ(þova) / %GFP
þ(-ova).
(B) Total ova-specific antibodies in prebleeds (d0, white bars; n ¼ 2 in each case) and 8 d after immunization (d8, grey bars; n ¼ 3 in each case) in
immunized and naive mice.
(C) Total splenocytes were isolated from mice that had received TH::iFoxp3 cells and were challenged with the indicated amounts of ova for 72 h in the
absence (white bars) or presence (grey bars) of 50 nM 4-OHT. The total proliferation was measured by
3H-thymidine incorporation, and the relative
proliferation was calculated as (þova / ( ova).
(D and E) Mice received 1 3 10
6 polyclonal TH::iFoxp3 cells and were immunized s.c. with ova in CFA. A week later, various tissues were analyzed.
(D) The total number of recovered TH::iFoxp3 cells from immunized mice (red, n ¼ 3) or nonimmunized mice (black, n ¼ 3) was calculated.
(E) The relative number of endogenous and TH::iFoxp3 cells was calculated as a ratio between immunized and nonimmunized mice. All error bars
represent SEM, and p-values were determined using an unpaired t-test.
doi:10.1371/journal.pbio.0060276.g004
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splenocytes from these mice and exposed them to ova ex
vivo. Although, in the absence of induction of iFoxp3, we
observed the expected antigen-induced recall proliferation,
we could not detect any proliferation above background in
the presence of 4-OHT (Figure 4C). This suggests that upon
iFoxp3 induction, the expanded TH::iFoxp3 cells became
anergic and suppressed the proliferation of the cotrans-
f e r r e d ,n o n t r a n s d u c e dD O 1 1 . 1 0Tc e l l sa sw e l la sa n y
endogenous ova-speciﬁc T cells.
To assess to what degree polyclonal TH::iFoxp3 cells
participate in an immune response, we transferred 1 3 10
6
wild-type TH::iFoxp3 cells into wild-type Balb/c mice. A week
after immunization with ova, we analyzed the lymphocytes
from various tissues by ﬂow cytometry. Whereas the number
of TH::iFoxp3 cells recovered from the blood, iliac lymph
nodes, liver, and spleen did not appear to change upon
antigenic challenge, we observed a marked increase in the
inguinal lymph nodes of the immunized mice (Figure 4D).
This indicates that some of the TH::iFoxp3 cells expanded in
the draining lymph nodes (subcutaneous [s.c.] immunization
into the ﬂanks). However, the number of endogenous cells in
the inguinal lymph nodes increased equally (Figure 4E),
suggesting that both populations expand to a similar degree
with their ratio remaining constant.
Figure 5. TH::iFoxp3 Cells Suppress Collagen-Induced Arthritis upon iFoxp3 Induction
(A and B) Arthritis was induced on day 0 by immunization with cII in CFA.
(A) Mice that received 1 3 10
6 TH::iFoxp3 cells (dark grey, n ¼ 17), mice that did not receive any further treatment (black, n ¼ 27), mice that received
tamoxifen injections (light grey, n ¼ 14), and mice that received 1 3 10
6 TH::iFoxp3 cells and tamoxifen injections to induce iFoxp3 (red, n ¼ 25) are
shown. The average arthritis scores of all mice in the groups are shown for each day.
(B) Maximum arthritis score reached by individual animals that had received no transfer of cells, TH::Foxp3 cells (see Figure 1A), and TH::iFoxp3 cells 6
tam. tam, tamoxifen.
(C and D) Arthritis was induced by immunization with cII in CFA.
(C) Mice that had received 1310
6 TH::iFoxp3 cells the day before cII immunization and tamoxifen injections (red, n¼4) when the mice reached a score
of 3 (day 0) and mice that did not receive any further treatment (black, n ¼ 9) are shown.
(D) Maximum arthritis score reached by individual animals. Error bars represent the SEM, and p-values were determined by Fisher’s Exact Test.
doi:10.1371/journal.pbio.0060276.g005
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To test the potential of TH::iFoxp3 cells in suppressing
autoimmune responses, we turned to the CIA model in which
TH::Foxp3 cells had failed to show an effect (Figure 1A). We
transferred 1–2 3 10
6 polyclonal TH::iFoxp3 cells into wild-
type DBA/1 mice 1 d prior to immunization with cII in CFA.
We induced iFoxp3 on day 15 after immunization, which lies
between the peak of the T cell response to collagen around
day 10 [44,45] and the onset of clinical symptoms around day
21 [46]. Mice that had received TH::iFoxp3 cells but did not
receive tamoxifen injections to induce iFoxp3 showed the
ﬁrst signs of arthritis on day 19, similar to the mice that
received no transfer of cells (Figure 5A). This effect was
speciﬁc to the antigenic challenge (cII in CFA) inducing the
autoimmune response, as mice receiving these cells without
immunization did not exhibit any overt signs of developing
autoimmune disease (Figure S3). Remarkably, 23 out of 25 of
the mice that had received TH::iFoxp3 cells and tamoxifen
injections to induce iFoxp3 did not show any clinical signs of
arthritis (scores ,3; Figure 5B). This is in stark contrast to the
other groups, in which the majority of animals developed
arthritis (scores  3; Figure 5B). Whereas tamoxifen has been
reported to have anti-inﬂammatory properties [47], we found
that by itself, it had only a minor effect on the development
of CIA (Figure 5A) and no effect on the activity of TH::control
cells in vivo (Figure S4). Despite the clear suppression of the
clinical signs of CIA, we could detect collagen-speciﬁc
antibodies in the serum of the animals at day 52, irrespective
of the treatment they had received (Figure S5).
Next, we investigated whether TH::iFoxp3 cells are capable
of stopping already established CIA. To this end, we waited
until the mice had reached a clinical score of 3 before
inducing iFoxp3. The induction appeared to completely halt,
if not reverse, CIA, leading to a decline in the average severity
score (Figure 5C). None of the mice showed a further increase
of symptoms after induction of iFoxp3 (Figure 5D).
Specificity of the Suppression
To assess whether the conversion of TH::iFoxp3 cells to TR
cell phenotype causes systemic immunosuppression, we
compared ‘‘ex vivo recall reactions’’ to the antigen used
prior to the induction of iFoxp3 (cII) to that of an unrelated
antigen (ova) injected after induction. The collagen-speciﬁc T
cell proliferation measured for mice in which iFoxp3 had
been induced was signiﬁcantly lower than that of mice that
had received no transfer of cells, albeit still higher than that
of naive mice (Figure 6A). As we did not add tamoxifen to the
ex vivo culture, this most likely reﬂects a lower number of cII-
speciﬁc proinﬂammatory T cells in the animals that had
received TH::iFoxp3 cells and tamoxifen induction, rather
than a mere ex vivo suppressive effect of TH::iFoxp3 cells.
Remarkably, we could not detect any difference in the T cell
proliferation upon exposure to ova irrespective of whether
the mice had received treatment or not (Figure 6B). This
suggests that the suppression only affects immune responses
in which the TH::iFoxp3 cells have had the opportunity to
participate prior to induction of iFoxp3. Indeed, we were
able to detect TH::iFoxp3 cells in the inﬂamed paw of cII-
immunized mice, suggesting that in the absence of induction
these cells can contribute to the inﬂammation (Figure S6)
However, once converted, the TH::iFoxp3 cells, despite still
being present (Figure S7A and S7B), seem to have lost the
capacity to suppress further unrelated immunological chal-
lenges (Figure 6B). This suggests that the conversion of
TH::iFoxp3 cells by induction of iFoxp3 does not lead to a
systemic immunosuppression.
Having shown that induced TH::iFoxp3 cells do not
suppress further unrelated immune responses postinduction,
we wanted to investigate the suppressive activity of TH::i-
Foxp3 cells in a context in which both cII and ova are present
prior to induction. We transferred 1 3 10
6 polyclonal
TH::iFoxp3 cells into wild-type DBA/1 mice 1 d before
immunization with a 1:1 mixture of ova and cII in CFA. We
induced iFoxp3 on day 15 after immunization and assessed
Figure 6. TH::iFoxp3 Cell-Mediated Suppression Is Specific
(A and B) Mice were immunized with cII in CFA on day 0. tam, tamoxifen.
(A) On day 35, ex vivo recall reactions to cII were performed on cells
purified from mice that did not receive any further treatment (control, n
¼ 10), mice that had received 1 3 10
6 TH::iFoxp3 cells and tamoxifen
injections (TH::iFoxp3 þ tam, n ¼ 10), and naive mice (naive, n ¼ 10).
(B) Some of the mice described in (A) were immunized on day 28 with
ova, and ex vivo recall reactions to ova were performed in parallel
(control, ova: n¼3,þova: n¼7; TH::iFoxp3þtam, ova: n¼3,þova: n¼
7; and naive,  ova: n ¼ 5, þova: n ¼ 5).
(C) Mice were immunized simultaneously with cII and ova in CFA on day
0. Ex vivo antigen-specific recall reactions to ova (closed) and cII (half-
closed) were performed on day 28. Mice that did not receive any further
treatment (naive, n ¼ 4), mice that received 1 3 10
6 TH::iFoxp3 cells and
tamoxifen injections (TH::iFoxp3þtam, n¼4), and mice that received 13
10
6 TH::iFoxp3 cells (TH::iFoxp3, n ¼ 4) are shown. p-Values were
determined using an unpaired t-test.
doi:10.1371/journal.pbio.0060276.g006
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Suppressing Immune Responses with iFoxp3Figure 7. TH::iFoxp3 Cell Longevity
(A) Representative FACS profiles of splenocytes purified from the indicated mice 52 d after transfer of 1 3 10
6 TH::iFoxp3 cells. tam, tamoxifen.
(B) Summary of the frequency of GFP
þ cells in the spleen 52 d after transfer (n ¼ 3 in each case).
(C) Representative FACS profiles of specified tissues 52 d after transfer of 2310
6 TH::iFoxp3 cells (n¼4 in each case; for auxiliary lymph node [aux. LN], a
pooled sample was analyzed).
(D) Summary of the frequency of TH::iFoxp3 cells in the various tissues 17 and 52 d after transfer.
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Suppressing Immune Responses with iFoxp3the antigen-induced proliferation of splenocytes prepared
from these mice on day 28. The recall proliferation against
ova and cII were comparable. Equally similar was the
reduction in proliferation in the cases in which iFoxp3 was
induced (Figure 6C). In combination, these results suggest
that this approach enables selective suppression without
affecting further unrelated immune responses after induc-
tion of iFoxp3.
TH::iFoxp3 Cell Longevity
It is noteworthy that we were able to detect TH::iFoxp3 cells
52 d after their transfer, independent of the level of arthritis
and whether the mice had received tamoxifen treatment or
not (Figure 7A and 7B). An analysis of various tissues revealed
that TH::iFoxp3 cells in blood were only marginally reduced
between day 17 and day 52 (Figure 7C and 7D), and could
readily be detected in the auxiliary lymph nodes and spleen.
Although this is likely to be of advantage with regard to
actively suppressing immune responses, it poses the question
whether continuous tamoxifen presence is required. Due to
the long half-life of tamoxifen [48], a direct assessment of this
in vivo is not feasible. However, in in vitro suppression assays,
TH::iFoxp3 cells had completely lost their suppressive activity
72 h after withdrawal of 4-OHT (Figure 7E). To perform these
experiments, we had to compensate for a marked reduction
in the number of viable TH::iFoxp3 cells that could be
recovered under these conditions. To formally address the
effect of the withdrawal of 4-OHT on TH::iFoxp3 cell viability,
we exposed the cells to 4-OHT for 48 h from the point of
transduction and then cultured them for a further 48 h in the
absence of 4-OHT. The number of viable cells was assessed by
ﬂow cytometry. Withdrawal of 4-OHT had no effect on
TH::control cells, but led to a marked decrease in the number
of TH::iFoxp3 cells (Figure 7F to 7H). This suggests, that once
induced, TH::iFoxp3 cells die upon tamoxifen withdrawal, but
it remains unclear how this translates into an in vivo context.
Indeed, it might be desirable to incorporate a suicide gene
[49] into the retroviral vector as this allows the removal of the
transduced cells if desired (Figure S8).
Discussion
Here, we have presented an approach that allows us to stop
undesirable immune responses without prior knowledge of
the antigens involved. TH::iFoxp3 cells participate in immune
responses as conventional TH cells until iFoxp3 is induced. At
this point, they change their phenotype from that of
proinﬂammatory T cells to that of regulatory T cells and
suppress the response they partook in.
Ectopic expression of Foxp3 in conventional T cells leads
to their conversion into cells with TR-like phenotype [19–21].
It was demonstrated early on that these TH::Foxp3 cells, like
TR cells, could suppress the development of colitis in
lymphopenic hosts [19,29]. However, it was noted that in this
context, the effectiveness of both polyclonal TH::Foxp3 cells
and TR cells [29,50,51] might be due to the regulation of
homeostatic expansion of the cotransferred, proinﬂamma-
tory cells, rather than to a true antigen-speciﬁc suppression
[9,11,52]. Furthermore, adoptive transfer of polyclonal TR
cells will only marginally increase the number of suppressive
cells that recognize a particular antigen. Indeed, the use of
polyclonal TR cell [22] or TH::Foxp3 populations [11,23]
(Figure 1A) have been of limited efﬁcacy, unless the immune
pathology was caused by an absence of functional TR cells
[20,53] or the experiments were performed in lymphopenic
animals [11]. The restrictions imposed by the low frequency
of antigen-speciﬁc TR or TH::Foxp3 cells in polyclonal
populations can be circumvented by ex vivo expansion of
antigen-speciﬁc TR cells and TCR transgenic TH::Foxp3 cells
[9–11,41]. Both approaches have been successfully exploited
in mouse models to treat diabetes [23,24,54,55], arthritis [31],
and experimental autoimmune encephalomyelitis (EAE) [56],
as well as being used for the induction of transplantation
tolerance [57,58]. Whereas TCR transgenic T cells are an
invaluable research tool to improve our understanding of the
regulation of immune responses [59,60], it is unclear to what
degree they can be used in a therapeutic context. Ex vivo
expansion of antigen-speciﬁc TR cells [9,11], or in vivo
conversion of TH into TR cells [12], promises to be more
applicable. However, these approaches are technically chal-
lenging, time consuming, and most importantly, require
knowledge of or access to the antigens involved in the
immune response to be suppressed [8,13].
Our study of TH::Foxp3 cells revealed a further problem.
Whereas TH::Foxp3 cells appear to adopt the characteristics
of TR cells in vitro, we found their homing to be altered from
that of endogenous TR and TH cells. This hinders the
TH::Foxp3 cells from mimicking the homing behavior of
endogenous TR cells, which has been shown to be important
for their suppressive function in vivo [61–63]. Those
TH::Foxp3 cells that fail to home to the secondary lymphoid
organs might not receive the required antigen priming [63]
and thus fail to expand like endogenous TR cells [64]. This
might explain the difference in the efﬁcacy of approaches
that use polyclonal Foxp3
þ cells and those that use antigen-
selected or TCR transgenic Foxp3
þ cells. The latter might
circumvent the need for an antigen-speciﬁc expansion in vivo
by ensuring that there are sufﬁcient numbers of antigen-
speciﬁc cells from the onset.
The activation-induced, Foxp3-mediated down-regulation
of CD62L might well be a key factor in the exclusion of
TH::Foxp3 cells from the peripheral lymph nodes since T cells
from CD62L-deﬁcient mice exhibit a similar phenotype
[34,35]. Further, it has been shown that CD62L
hi polyclonal
TR cells have a more potent protective effect in vivo [65].
However, we cannot exclude that ectopic expression of Foxp3
also alters the expression of other homing receptors. Indeed,
(E–H) TH::iFoxp3 cell survival upon 4-OHT withdrawal (E). TH::control and TH::iFoxp3 were cultured in the continuous presence [þ.þ] or absence [ . ]
of 50 nM 4-OHT. In the case of [þ. ], 4-OHT was withdrawn for 72 h after an initial induction for 48 h, before their suppressive activity was measured. A
total of 1310
5 cells of the indicated populations were cocultured at a 1:1 ratio with 1310
5 CD4
þCD25
  target cells in 96-well plates coated with anti-
CD3e [0.6 lg/ml]. The proliferation of the cells was measured after 72 h based on
3H-thymidine incorporation (n¼3 in each case). (F–H) TH::control and
TH::iFoxp3 were cultured in the presence or absence of 4-OHT (50 nM) and anti-CD3e (0.6 lg/ml). After 48 h, 4-OHT and anti-CD3e was withdrawn. The
viability of the cells was assessed by flow cytometry at 0 h, 24 h, and 48 h by measuring the coexpression of GFP.
(F) Ratio of cells after 4-OHT withdrawal and cells that were cultured in the absence of 4-OHT from the start.
(G and H) Representative FACS profiles of TH::control and TH::iFoxp3 cells. All error bars represent the SEM.
doi:10.1371/journal.pbio.0060276.g007
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CD62L in thymically derived TR and TH cells was not
sufﬁcient to exclude them from the peripheral lymph nodes.
Here, we present an approach that addresses these
problems by transducing polyclonal, conventional T cells
with a retroviral vector encoding a genetically engineered
inducible form of Foxp3. TH::iFoxp3 cells retain their
proinﬂammatory character and the ability to home to the
lymph nodes. Those TH::iFoxp3 cells that recognize an
antigen appear to participate in the immune response and
expand. This in vivo expansion of antigen-speciﬁc TH::iFoxp3
cells circumvents the need for an ex vivo expansion and does
not rely on any knowledge of the antigens involved. Upon
induction of iFoxp3, the in vivo expanded, antigen-speciﬁc
TH::iFoxp3 cells assume a TR cell-like phenotype and suppress
the undesirable response they initially partook in. We were
able to demonstrate the efﬁcacy of our approach by
speciﬁcally halting CIA in a mouse model. Importantly,
TH::iFoxp3 cell-mediated suppression appears to be re-
stricted to the speciﬁc response, which is ongoing at the time
of induction of iFoxp3. Those TH::iFoxp3 cells that do not
already participate in an immune response at the time of
induction lose the capacity to suppress further unrelated
immune responses despite still being present. Although we
cannot exclude that other factors play a role, it appears that
the antigen-speciﬁc expansion of the TH::iFoxp3 cells prior to
induction is an integral part of the observed nonsystemic
suppression. In a therapeutic context, it might be desirable to
limit the exposure to tamoxifen to minimize possible side
effects. Although it appears that most TH::iFoxp3 cells die
upon withdrawal of tamoxifen, those that do survive lose
their suppressive activity. To avoid possible deleterious
effects, these ‘‘revertant’’ cells can be removed based on the
incorporation of a suicide gene into the retroviral vector
used for the delivery of iFoxp3.
We believe that this strategy of induced conversion of TH
cells into cells with a TR cell-like phenotype using iFoxp3 is
generally applicable and will allow us to stop a variety of
undesirable immune responses.
Materials and Methods
Animals and cell preparations. Balb/c and DBA/1 mice (8–12 wk
old) were purchased from Charles River and Harlan. DO11.10xSCID
mice on the Balb/c background were kindly provided by Caetano Reis
e Sousa, CRUK. Animals were maintained under speciﬁc pathogen-
free conditions. Expert animal technicians provided animal care in
compliance with the relevant laws and institutional guidelines. Cells
used for in vivo and ex vivo experiments were puriﬁed (.90% purity)
using an AutoMACS (Miltenyi Biotec) as previously described [66].
Flow cytometric analysis and proliferation assays were performed as
described previously [66] using the following antibodies: ratCD8a (BD
Bioscience), CD62L (BD Bioscience), CD4 (BD Bioscience), CD25 (BD
Bioscience), and Foxp3 (eBioscience).
Retroviral vectors and transduction. Foxp3 was ampliﬁed from
total spleen cDNA and iFoxp3 was constructed by a C-terminal fusion
of ERT2 in place of the stop codon. Both were cloned into m6p
retroviral vectors coexpressing either GFP or a GPI-linked rat CD8a
marker. For the measurement of in vivo translocation of iFoxp3, GFP
was cloned in-frame with Foxp3 after the ﬁrst ﬁve codons in the 59-
end [67] in order to produce GFP-iFoxp3. For the production of
retroviral supernatant, 293eT cells were cotransfected with an equal
amount of pCl-Eco packaging plasmid and the respective m6p
retroviral construct. Supernatant was harvested at 36 h and 48 h after
transfection, ﬁltered, and then used immediately. For retroviral
transduction, the freshly puriﬁed CD4
þCD25
  T cells were activated
in the presence of plate-bound anti-CD3e (0.6 lg/ml) (BD Bioscience)
and 10 U/ml of recombinant mIL-2 (PeproTech). Cells were
transduced at 24 h and 36 h after activation by resuspension in a
1:2 mixture of supernatant and complete medium (RPMI/10% FCS/10
lM b-mercaptoethanol/50 lg/ml gentamicin) supplemented with 10 U
mIL-2 and 6 lg/ml protamine sulphate (Sigma) and 10 U/ml mIL2,
followed by centrifugation at 6003g for 2 h at 32 8C. Six hours after
transduction, cells were resuspended in complete medium containing
10 U mIL-2. A ﬁxed ratio of transduced (50%–60% in all cases) and
nontransduced cells was adoptively transferred into mice 72 h after
the last transduction.
Collagen-induced arthritis and gene induction. Male DBA/1 mice
received 1–2 3 10
6 transduced cells intravenously (i.v.) (day  1) and
were immunized intradermally (i.d.) with 100 ll of cII (Sigma,)
dissolved in 10 mM acetic acid and emulsiﬁed (1 lg/ll) in CFA
(DIFCO) the following day (day 0) [46]. The mice were assessed
(blinded) on a daily basis, and inﬂammation of the paws was scored as
follows: grade 0—no swelling; grade 1—swelling in an individual joint;
grade 2—swelling in more than one joint or mild inﬂammation of the
paw; and grade 3—severe swelling of the entire paw and/or ankylosis.
Each paw was graded, and all scores where totaled for a maximum
score of 12 per mouse. Mice reaching a score of 8 or more were
euthanized in accordance with restrictions imposed by UK legis-
lation. For iFoxp3 induction, the mice were injected i.p. with 100 llo f
tamoxifen (in a 10:1 mixture of sunﬂower oil:ethanol [10 lg/ll
tamoxifen]) on days 15 and 16, and (in a 10:1 mixture of sunﬂower
oil:ethanol [1 lg/ll tamoxifen]) on days 23, 29, 30, 36, and 43.
Alternatively, iFoxp3 was induced once the mice had reached a score
of 3 (day 0) by i.p. injections with 100 ll of tamoxifen (in a 10:1
mixture of sunﬂower oil:ethanol [10 lg/ll tamoxifen]) on days 1, 2, 9,
and 16.
In vivo expansion of antigen-speciﬁc T cells and ova-speciﬁc
suppression assay. CD4
þCD25
  T cells were puriﬁed from 6–12-wk-
old female SCIDxDO11.10 mice and transduced with Foxp3 or
iFoxp3 as described above. Balb/c females received i.v. 5310
4 of a 2:3
ratio of transduced and nontransduced cells. Three days later, each
mouse was immunized s.c. with either ova (Sigma) in CFA (50 lg/
mouse) or just with CFA. The mice were sacriﬁced and analyzed 8 d
after immunization. For ova-speciﬁc suppression assays, total
splenocytes were prepared as described [66], resuspended in
complete medium, and then plated into round-bottom 96-well plates
(density of 2310
5 cells/well). iFoxp3 was induced by adding 50 nM 4-
OHT (Sigma). Ova was added to the cells 16 h after induction. After
60 h, the cells were pulsed with 1 lCi of
3H-thymidine (Amersham),
collected at 72 h with a Filtermate Harvester (Packard), and analyzed
with a TopCount scintillation counter (Packard) according to the
manufacturer’s instructions.
Collagen- and ova-speciﬁc ex vivo recall reactions. CIA and iFoxp3
induction was performed as described above. On day 28, some of the
mice received ova in CFA s.c. into both ﬂanks (100 lg/mouse). Total
splenocytes were prepared on day 35 and plated into round-bottom
96-well plates at a density of 5 3 10
5 cells/well. Proliferation of the
cells was measured 72 h after addition of either ova (100 lg/ml) or cII
(100 lg/ml) as described above. Alternatively, mice were immunized
simultaneously with ova and cII on day 0 by i.d. injection of a mixture
of 100 lg of ova and 100 lg of cII in CFA. Recall reactions were
performed on day 28 as described above at a density of 2 310
5 cells/
well.
Elisa for the detection of collagen- and ova-speciﬁc antibodies.
Ninety-six–well ﬂat-bottom plates (Nunc) were coated with either ova
(50 lg/ml) or cII (2 lg/ml) at 4 8C for 16 h and blocked with 1% BSA in
PBS for 1 h. A total of 50 ll of serial dilutions (starting at 1:50 for ova
and 1:10,000 for cII) of mouse sera in PBS were incubated for 2 h.
Biotin-conjugated IgG1, IgG2a, IgG2b, and IgG3 (BD Bioscience) were
then applied for 2 h. For ova detection, IgM (BD Bioscience) was also
included. The development of cII and ova-speciﬁc immunoglobulins
was then measured using a DuoSet kit (R&D Systems) according to the
manufacturer’s instructions.
Real-time reverse transcriptase PCR. Total RNA was extracted
using an RNeasy kit (Qiagen) including DNaseI treatment (Invitro-
gen). cDNA was synthesized with Superscript II (Invitrogen) with
random hexamer primers (Amersham) following the manufacturers
instructions. Real-time PCR was performed using Taqman SYBR
green PCR master mix (Applied Biosystems) with primers speciﬁc for
Sell (CD62L) and Hprt. The sequences used were: Sell primers: 59-ATG
CAG TCC ATG GTA CCC AAC TCA-39 and 59-CTG CAG AAA CAC
AGT GTG GAG CAT-39; Hprt primers: 59-TTA AGC AGT ACA GCC
CCA AAA TG-39 and 59-CAA ACT TGT CTG GAA TTT CAA ATC C-
39. An ABI Prism 7900 sequence detection system (Applied
Biosystems) was used for 45 cycles of PCR according to the
manufacturer’s instructions.
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Figure S1. Foxp3 and Control Retroviral Vectors
Diagram of Foxp3 containing retroviral vectors either coexpressing
GFP (m6pg[iFoxp3]) or a GPI-linked ratCD8 a-chain (m6p8[iFoxp3]),
and retroviral vectors containing blasticidine-S-deaminase (bsd) as a
control gene either coexpressing GFP (m6pg[control]) or a GPI-
linked ratCD8 a-chain (m6p8[control]).
Found at doi:10.1371/journal.pbio.0060276.sg001 (114 KB PDF).
Figure S2. Activation-Mediated Down-Regulation of CD62L in T
Cells
(A and B) CD62L expression on CD4
þCD25
  TH cells (black) and
CD4
þCD25
þ TR cells (red). (A) Representative ﬂuorescence-activated
cell sorter (FACS) proﬁles for CD62L expression on TH and TR cells
prepared from spleen (n ¼ 2) and activated with aCD3e, aCD28, and
IL-2 for the indicated length of time. (B) Representative graph of the
relative mRNA levels of Sell (CD62L) in CD4
þCD25
  TH and
CD4
þCD25
þ TR cells activated for the indicated length of time (n ¼
2) determined by quantitative PCR (qPCR) and normalized to Hprt.
(C) Comparison of the homing behavior of activated m6pg[control]-
transduced CD4
þCD25
 TH (black, n¼8) and CD4
þCD25
þTR (red, n¼
8) cells. A total of 1310
6 cells were transferred into each mouse, and
the tissues were analyzed 48 h later by ﬂow cytometry as described
above.
Found at doi:10.1371/journal.pbio.0060276.sg002 (408 KB PDF).
Figure S3. Adoptive Transfer of TH::iFoxp3 Cells Does Not Lead to
any Overt Signs of Autoimmune Disease
Balb/c mice received 2 3 10
6 TH::iFoxp3 cells (red, n ¼ 7) or no cells
(black, n ¼ 5) and were visually inspected and weighed weekly for 11
wk.
Found at doi:10.1371/journal.pbio.0060276.sg003 (259 KB PDF).
Figure S4. Tamoxifen Treatment Has No Effect on TH::Control Cells
In Vivo
Total splenocytes were isolated from mice that had received no
transfer of cells or 1310
6 polyclonal TH::control and were challenged
with ova in CFA. Some of the mice were injected with tamoxifen on
day 4 after immunization (n¼3 in all cases). The relative proliferation
is shown as a ratio of thymidine incorporation in the presence or
absence of ova stimulation in the recall reaction performed on day 7.
All error bars represent the standard error of the mean (SEM), and
the p-values were determined using an unpaired t-test.
Found at doi:10.1371/journal.pbio.0060276.sg004 (276 KB PDF).
Figure S5. Level of Collagen-Speciﬁc IgG Antibodies
Levels of collagen-speciﬁc IgG1, IgG2a, IgG2b, and IgG3 on day  2
and 52 in control mice (black, n ¼ 6) and mice that had received
TH::iFoxp3 cells and tamoxifen injections (red, n ¼ 6). All error bars
represent the SEM.
Found at doi:10.1371/journal.pbio.0060276.sg005 (131 KB PDF).
Figure S6. Migration of TH::iFoxp3 Cells into the Inﬂamed Paw
Mice received either 1310
6 TH::iFoxp3 cells or no cell transfer (n¼2
in both cases). Arthritis was induced on day 0 by immunization with
cII in CFA. The front and hind paws of arthritic mice were dissected
on day 45, and the GFP
þ cells were detected by ﬂow cytometry. Error
bars represent the SEM.
Found at doi:10.1371/journal.pbio.0060276.sg006 (260 KB PDF).
Figure S7. Survival of TH::iFoxp3 Cells in the Presence or Absence of
Antigen
Mice received 1 3 10
6 polyclonal TH::iFoxp3 cells on day 0 and were
immunized with ova as indicated on day 5. Some of the mice also
received tamoxifen injections either on day 0 or day 8. The number
of TH::iFoxp3 cells present in the spleen was assessed by ﬂow
cytometry based on GFP expression on day 13.
(A) Representative FACS proﬁles.
(B) Summary of the relative number of GFP
þ cells in the spleen
normalized to the total number of recovered cells (n ¼ 3 in absence
and n ¼ 4 in the presence of ova immunization). All error bars
represent the SEM.
Found at doi:10.1371/journal.pbio.0060276.sg007 (218 KB PDF).
Figure S8. In Vivo Depletion of TH::GFP/TK Cells
CD4
þCD25
  T cells were transduced with a retroviral vector
containing GFP coexpressing a herpes simplex thymidine kinase
gene (m6ptk[GFP]). Twenty-four hours after transduction, 1 3 10
6
cells were transferred into wild-type mice (day 0). Ganciclovir (1 mg/
mouse) was administered for three consecutive days by i.p. injection;
and on day 5, the inguinal lymph nodes and spleen were analyzed for
the presence of TH::GFP/TK cells (n ¼ 4 in all cases). All error bars
represent the SEM.
Found at doi:10.1371/journal.pbio.0060276.sg008 (117 KB PDF).
Acknowledgments
We would like to thank Doug Fearon, Michael Neuberger, and Greg
Winter for critical reading of the manuscript, and Felix Randow for
provision of the retroviral vectors system as well as many helpful
discussions. We would also like to thank Martin Reed, Sally Thomas,
and Graham Ledger for expert animal care.
Author contributions. KGA and AGB conceived and designed the
experiments. KGA, TB, and AGB performed the experiments. KGA
and AGB analyzed the data. KGA and AGB wrote the paper.
Funding. KGA is recipient of a scholarship from the Carlsberg
Foundation. All work was performed at the Laboratory of Molecular
Biology and funded by the Medical Research Council and in part
supported by the Arthritis Research Campaign (ARC; project grant
18297).
Competing interests. The authors have declared that no competing
interests exist.
References
1. Rioux JD, Abbas AK (2005) Paths to understanding the genetic basis of
autoimmune disease. Nature 435: 584–589.
2. Gummert JF, Ikonen T, Morris RE (1999) Newer immunosuppressive drugs:
a review. J Am Soc Nephrol 10: 1366–1380.
3. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, et al. (2007) New
reagents on the horizon for immune tolerance. Annu Rev Med 58: 329–346.
4. Sakaguchi S (2004) Naturally arising CD4þ regulatory t cells for
immunologic self-tolerance and negative control of immune responses.
Annu Rev Immunol 22: 531–62562.
5. Aluvihare VR, Kallikourdis M, Betz AG (2004) Regulatory T cells mediate
maternal tolerance to the fetus. Nat Immunol 5: 266–271.
6. Trowsdale J, Betz AG (2006) Mother’s little helpers: mechanisms of
maternal-fetal tolerance. Nat Immunol 7: 241–246.
7. Darrasse-Jeze G, Klatzmann D, Charlotte F, Salomon BL, Cohen JL (2006)
CD4þCD25þ regulatory/suppressor T cells prevent allogeneic fetus rejec-
tion in mice. Immunol Lett 102: 106–109.
8. Bluestone JA, Thomson AW, Shevach EM, Weiner HL (2007) What does the
future hold for cell-based tolerogenic therapy? Nat Rev Immunol 7: 650–
654.
9. Bluestone JA (2005) Regulatory T-cell therapy: is it ready for the clinic? Nat
Rev Immunol 5: 343–349.
10. von Boehmer H (2006) Can studies of tolerance ever lead to therapy? Ann
Rheum Dis 65: iii41–43.
11. Masteller EL, Tang Q, Bluestone JA (2006) Antigen-speciﬁc regulatory T
cells–ex vivo expansion and therapeutic potential. Semin Immunol 18: 103–
110.
12. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, et al.
(2005) Inducing and expanding regulatory T cell populations by foreign
antigen. Nat Immunol 6: 1219–1227.
13. Kretschmer K, Heng TS, von Boehmer H (2006) De novo production of
antigen-speciﬁc suppressor cells in vivo. Nat Protoc 1: 653–661.
14. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25þCD4þ
regulatory T cells in immunological tolerance to self and non-self. Nat
Immunol 6: 345–352.
15. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell
lineage. Nat Immunol 8: 457–462.
16. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal
developmental pathways for the generation of pathogenic effector TH17
and regulatory T cells. Nature 441: 235–238.
17. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of
peripheral CD4þCD25- naive T cells to CD4þCD25þ regulatory T cells by
TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875–
1886.
18. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004)
Cutting edge: TGF-beta induces a regulatory phenotype in CD4þCD25- T
cells through Foxp3 induction and down-regulation of Smad7. J Immunol
172: 5149–5153.
19. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell
development by the transcription factor Foxp3. Science 299: 1057–1061.
PLoS Biology | www.plosbiology.org November 2008 | Volume 6 | Issue 11 | e276 2412
Suppressing Immune Responses with iFoxp320. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the
development and function of CD4þCD25þregulatory T cells. Nat Immunol
4: 330–336.
21. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for
Scurﬁn in CD4þCD25þ T regulatory cells. Nat Immunol 4: 337–342.
22. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM (2004) CD25þCD4þ
T cells, expanded with dendritic cells presenting a single autoantigenic
peptide, suppress autoimmune diabetes. J Exp Med 199: 1467–1477.
23. Jaeckel E, von Boehmer H, Manns MP (2005) Antigen-speciﬁc FoxP3-
transduced T-cells can control established type 1 diabetes. Diabetes 54:
306–310.
24. Green EA, Choi Y, Flavell RA (2002) Pancreatic lymph node-derived
CD4(þ)CD25(þ) Treg cells: highly potent regulators of diabetes that require
TRANCE-RANK signals. Immunity 16: 183–191.
25. Floess S, Freyer J, Siewert C, Baron U, Olek S, et al. (2007) Epigenetic
control of the foxp3 locus in regulatory T cells. PLoS Biol 5: e38. doi:10.
1371/journal.pbio.0050038
26. Selvaraj RK, Geiger TL (2007) A kinetic and dynamic analysis of foxp3
induced in T cells by TGF-beta. J Immunol 178: 7667–7677.
27. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, et al. (2007) Reciprocal
TH17 and regulatory T cell differentiation mediated by retinoic acid.
Science 317: 256–260.
28. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, et al. (2007) Small
intestine lamina propria dendritic cells promote de novo generation of
Foxp3 T reg cells via retinoic acid. J Exp Med 204: 1775–1785.
29. Mottet C, Uhlig HH, Powrie F (2003) Cutting edge: cure of colitis by
CD4þCD25þ regulatory T cells. J Immunol 170: 3939–3943.
30. Loser K, Hansen W, Apelt J, Balkow S, Buer J, et al. (2005) In vitro-
generated regulatory T cells induced by Foxp3-retrovirus infection control
murine contact allergy and systemic autoimmunity. Gene Ther 12: 1294–
1304.
31. Fujio K, Okamoto A, Araki Y, Shoda H, Tahara H, et al. (2006) Gene
therapy of arthritis with TCR isolated from the inﬂamed paw. J Immunol
177: 8140–8147.
32. Brand DD, Kang AH, Rosloniec EF (2003) Immunopathogenesis of collagen
arthritis. Springer Semin Immunopathol 25: 3–18.
33. Boehm T, Bleul CC (2007) The evolutionary history of lymphoid organs.
Nat Immunol 8: 131–135.
34. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, et al. (1994)
Lymphocyte homing and leukocyte rolling and migration are impaired in
L-selectin-deﬁcient mice. Immunity 1: 247–260.
35. Rosen SD (2004) Ligands for L-selectin: homing, inﬂammation, and beyond.
Annu Rev Immunol 22: 129–156.
36. Smalley DM, Ley K (2005) L-selectin: mechanisms and physiological
signiﬁcance of ectodomain cleavage. J Cell Mol Med 9: 255–266.
37. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3
controls regulatory T cell function through cooperation with NFAT. Cell
126: 375–387.
38. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. (2007)
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.
Nature 446: 685–689.
39. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al.
(2007) Foxp3 occupancy and regulation of key target genes during T-cell
stimulation. Nature 445: 931–935.
40. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, et al. (2007) Genome-
wide analysis of Foxp3 target genes in developing and mature regulatory T
cells. Nature 445: 936–940.
41. Roncarolo MG, Battaglia M (2007) Regulatory T-cell immunotherapy for
tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7:
585–598.
42. Feil R, Wagner J, Metzger D, Chambon P (1997) Regulation of Cre
recombinase activity by mutated estrogen receptor ligand-binding do-
mains. Biochem Biophys Res Commun 237: 752–757.
43. Rossant J, McMahon A (1999) "Cre"-ating mouse mutants–a meeting review
on conditional mouse genetics. Genes Dev 13: 142–145.
44. Pogue-Caley RR, McHeyzer-Williams MG (2001) Emergence of a type II
collagen-speciﬁc helper T cell response. Eur J Immunol 31: 2362–2372.
45. Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF (2005) Ex vivo
characterization of the autoimmune T cell response in the HLA-DR1
mouse model of collagen-induced arthritis reveals long-term activation of
type II collagen-speciﬁc cells and their presence in arthritic joints. J
Immunol 174: 3978–3985.
46. Rosloniec EF, Cremer M, Kang A, Myers LK (2001) Collagen-induced
arthritis. Curr Protoc Immunol 15.5: 15.5.1–15.5.24.
47. Grainger DJ, Metcalfe JC (1996) Tamoxifen: teaching an old drug new
tricks? Nat Med 2: 381–385.
48. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, et
al. (2001) Correlation between tamoxifen elimination and biomarker
recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev
10: 967–970.
49. Straathof KC, Spencer DM, Sutton RE, Rooney CM (2003) Suicide genes as
safety switches in T lymphocytes. Cytotherapy 5: 227–230.
50. Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated
antigen 4 plays an essential role in the function of CD25(þ)CD4(þ)
regulatory cells that control intestinal inﬂammation. J Exp Med 192: 295–
302.
51. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W,
et al. (2005) Effective treatment of collagen-induced arthritis by adoptive
transfer of CD25þ regulatory T cells. Arthritis Rheum 52: 2212–2221.
52. Li J, Bracht M, Shang X, Radewonuk J, Emmell E, et al. (2006) Ex vivo
activated OVA speciﬁc and non-speciﬁc CD4þCD25þ regulatory T cells
exhibit comparable suppression to OVA mediated T cell responses. Cell
Immunol 241: 75–84.
53. Asano M, Toda M, Sakaguchi N, Sakaguchi S (1996) Autoimmune disease as
a consequence of developmental abnormality of a T cell subpopulation. J
Exp Med 184: 387–396.
54. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al. (2004) In vitro-
expanded antigen-speciﬁc regulatory T cells suppress autoimmune
diabetes. J Exp Med 199: 1455–1465.
55. Tarbell KV, Petit L, Zuo X, Toy P, Luo X, et al. (2007) Dendritic cell-
expanded, islet-speciﬁc CD4þ CD25þ CD62Lþ regulatory T cells restore
normoglycemia in diabetic NOD mice. J Exp Med 204: 191–201.
56. Hori S, Haury M, Coutinho A, Demengeot J (2002) Speciﬁcity requirements
for selection and effector functions of CD25þ4þ regulatory T cells in anti-
myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U
S A 99: 8213–8218.
57. Chai JG, Xue SA, Coe D, Addey C, Bartok I, et al. (2005) Regulatory T cells,
derived from naive CD4þCD25- T cells by in vitro Foxp3 gene transfer, can
induce transplantation tolerance. Transplantation 79: 1310–1316.
58. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively
expands CD4þCD25þFoxP3þ regulatory T cells. Blood 105: 4743–4748.
59. Bluthmann H, Kisielow P, Uematsu Y, Malissen M, Krimpenfort P, et al.
(1988) T-cell-speciﬁc deletion of T-cell receptor transgenes allows func-
tional rearrangement of endogenous alpha- and beta-genes. Nature 334:
156–159.
60. Stefanova I, Dorfman JR, Germain RN (2002) Self-recognition promotes the
foreign antigen sensitivity of naive T lymphocytes. Nature 420: 429–434.
61. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, et al. (2006) In vivo
dynamics of regulatory T cell trafﬁcking and survival predict effective
strategies to control graft-versus-host disease following allogeneic trans-
plantation. Blood 109: 2649–2656.
62. Sather BD, Treuting P, Perdue N, Miazgowicz M, Fontenot JD, et al. (2007)
Altering the distribution of Foxp3þ regulatory T cells results in tissue-
speciﬁc inﬂammatory disease. J Exp Med 204: 1335–47.
63. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, et al. (2005) Lymph node
occupancy is required for the peripheral development of alloantigen-
speciﬁc Foxp3þ regulatory T cells. J Immunol 174: 6993–7005.
64. Klein L, Khazaie K, von Boehmer H (2003) In vivo dynamics of antigen-
speciﬁc regulatory T cells not predicted from behavior in vitro. Proc Natl
Acad Sci U S A 100: 8886–8891.
65. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, et al.
(2004) L-selectin(hi) but not the L-selectin(lo) CD4þ25þ T-regulatory cells
are potent inhibitors of GVHD and BM graft rejection. Blood 104: 3804–
3812.
66. Kallikourdis M, Andersen KG, Welch KA, Betz AG (2006) Alloantigen-
enhanced accumulation of CCR5þ’effector’ regulatory T cells in the gravid
uterus. Proc Natl Acad Sci U S A 104: 594–599.
67. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005)
Regulatory T cell lineage speciﬁcation by the forkhead transcription factor
foxp3. Immunity 22: 329–341.
PLoS Biology | www.plosbiology.org November 2008 | Volume 6 | Issue 11 | e276 2413
Suppressing Immune Responses with iFoxp3